Cataracts, dry eyes, glaucoma and other eye problems become more common with age. But these can be treated — and sometimes ...

The Food and Drug Administration (FDA) has approved Susvimo ® (ranibizumab injection) for the treatment of patients with diabetic macular edema (DME) who have previously responded to at least 2 ...

The U.S. Food and Drug Administration has approved Genentech's Susvimo (ranibizumab) 100 mg/mL for treating diabetic macular ...

“Susvimo presents a unique, convenient treatment alternative to routine eye injections ... hemorrhage. Susvimo is also indicated for the treatment of neovascular (wet) age-related macular ...

Intravitreal injections, including those with Lucentis, have been associated with endophthalmitis, retinal detachment ... included conjunctival hemorrhage, eye pain, vitreous floaters, and ...

The safety profile remained consistent with previous studies, with common side effects being cataract and retinal hemorrhage ... are administered by injection into the eye. You should not use ...

Eye injections are a treatment, not a cure for this condition, and patients often need frequent injections to maintain their vision. While a diagnosis of macular degeneration can seem scary ...

Susvimo is the first and only FDA-approved treatment shown to maintain vision in people with DME with fewer treatments than standard-of-care eye injections. Susvimo is now available to US retina ...

4D-150 shows significant reduction in injection ... vascular retinal diseases, potentially improving patient quality of life by reducing frequent injection burdens. 3E10 vg/eye showed an 83% ...

WEDNESDAY, Feb. 5, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Susvimo (ranibizumab) 100 mg/mL for treating diabetic macular ... injections (9.6 and 9.4 eye chart ...